Identification of three 11p11.2 candidate liver tumor suppressors through analysis of known human genes

Molecular Carcinogenesis

Volumn 36, Issue 2, 2003, Pages 90-99

  Ricketts, Sharon L ^a   Carter, Jennifer C ^a   Coleman, William B ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

Chromosome transfer; EST; Hepatocellular carcinoma; Human 11p11.2; Microcell hybrid; Tumor suppressor gene

Indexed keywords

GUANINE NUCLEOTIDE BINDING PROTEIN; MITOCHONDRIAL CARRIER HOMOLOG 2 PROTEIN; PROTEIN P53 INDUCED PROTEIN; PROTEIN PIG11; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CANCER INHIBITION; CELL LINE; CHROMOSOME 11P; CHROMOSOME MAP; CONTROLLED STUDY; CYTOGENETICS; EXPRESSED SEQUENCE TAG; GENE EXPRESSION; GENE IDENTIFICATION; HUMAN; HUMAN CELL; HYBRID CELL; LIVER CANCER; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; MEDICAL GENETICS; NONHUMAN; PRIORITY JOURNAL; RAT; TUMOR SUPPRESSOR GENE;

ANIMALS; CHROMOSOME DELETION; CHROMOSOMES, HUMAN, PAIR 11; EXPRESSED SEQUENCE TAGS; GENE EXPRESSION PROFILING; GENES, TUMOR SUPPRESSOR; GENETIC MARKERS; HUMANS; LIVER NEOPLASMS; PHYSICAL CHROMOSOME MAPPING; RATS; RNA, MESSENGER; TRANSCRIPTION, GENETIC; TUMOR CELLS, CULTURED;

EID: 0037314052     PISSN: 08991987     EISSN: None     Source Type: Journal    
DOI: 10.1002/mc.10101     Document Type: Article

References (58)

1. Grisham JW. Molecular genetic alterations in primary hepatocellular neoplasms. In: Coleman WB, Tsongalis GJ, editors. The molecular basis of human cancer. Totowa: Humana; 2002. p 269-346.
2. Thorgeirsson SS, Grisham JW. Molecular carcinogenesis of hepatocellular carcinoma: A genomically heterogeneous multi-pathway process. Nat Genet 2002;339-346.
3. Boige V, Laurent-Puig P, Fouchet P, et al. Concerted nonsyntenic allelic losses in hyperploid hepatocellular carcinoma as determined by a high-resolution allelotype. Cancer Res 1997;57:1986-1990.
4. Nagai H, Pineua P, Tiollais P, Buendia MA, Dejean A. Comprehensive allelotyping of human hepatocellular carcinoma. Oncogene 1997;14:2927-2933.
5. Piao Z, Park C, Park J-H, Kim H. Allelotype analysis of hepatocellular carcinoma. Int J Cancer 1998;75:29-33.
6. Fujimori M, Tokino T, Hino O, et al. Allelotype study of primary hepatocellular carcinoma. Cancer Res 1991;51:89-93.
7. Wang HP, Rogler CE. Deletions of human chromosome arms 11p and 13q in primary hepatocellular carcinomas. Cytogenet Cell Genet 1988;48:72-78.
8. Walker GJ, Hayward NK, Falvey S, Cooksley WGE. Loss of somatic heterozygosity in hepatocellular carcinoma. Cancer Res 1991;51:4367-4370.
9. Sheu J-C, Lin Y-W, Chou H-C, et al. Loss of heterozygosity and microsatellite instability in hepatocellular carcinoma in Taiwan. Br J Cancer 1999;80:468-476.
10. Buetow KH, Murray JC, Israel JL, et al. Loss of heterozygosity suggests tumor suppressor gene responsible for primary hepatocellular carcinoma. Proc Natl Acad Sci USA 1989;86:8852-8856.
11. Zhang W, Hirohashi S, Tsuda H, et al. Frequent loss of heterozygosity on chromosomes 16 and 4 in human hepatocellular carcinoma. Jpn J Cancer Res 1990;81:108-111.
12. Nowell PC, Morris HP, Potter VR. Chromosomes of 'minimal deviation' hepatomas and some other transplantable rat tumors. Cancer Res 1967;27:1565-1579.
13. Wolman SR, Phillips TF, Becker FF. Fluorescent banding patterns of rat chromosomes in normal cells and primary hepatocellular carcinomas. Science 1972;175:1267-1269.
14. Masuji H. A non-random pattern in the initial chromosome aberrations in two diploid lines of rat liver cells. Gann 1974;65:429-438.
15. Becker FF, Wolman SR, Asofsky R, Sell S. Sequential analysis of transplantable hepatocellular carcinomas. Cancer Res 1975;35:3021-3026.
16. Kovi E, Morris HP. Chromosome banding studies in several transplantable hepatomas. Adv Enzyme Reg 1976;14:139-162.
17. Mullen NT, Barrett CA. Banded karyotypes of H-4-IIE-3C rat hepatoma cells grown in vitro. In Vitro Cell Mol Biol 1976;12:658-664.
18. Olah E, Weber G. Giemsa-banding karyotype of rat hepatomas of different growth rates. Cancer Res 1979;39:1708-1717.
19. Kovi J, Kovi E, Morris HP, Rao MS. Chromosome banding patterns of three transplantable hepatomas induced in rats by aromatic amines. J Natl Cancer Inst 1987;61:495-506.
20. Holecek BV, Kerler R, Rabes HM. Chromosomal analysis of a diethylnitrosamine-induced tumorigenic and nontumorigenic rat liver cell line. Cancer Res 1989;49:3024-3028.
21. Iype PT, Malan-Shibley L, Raychaudhuri R. Sequential chromosomal alterations in rat liver epithelial cells during aflatoxin-induced neoplastic transformation in vitro. J Toxicol-Toxin Rev 1989;8:195-216.
22. Herens C, Alvarez Gonzalez ML, Barbason H. Cytogenetic changes in hepatocellular carcinomas from rats treated with chronic exposure to diethylnitrosamine. Cancer Genet Cytogenet 1992;60:45-52.
23. Sargent LM, Sattler GL, Roloff B, et al. Ploidy and specific karyotypic changes during promotion with phenobarbital, 2,5,2′,5′-tetrachlorobiphenyl, and or 3,4,3′,4′-tetrachlorobiphenyl in rat liver. Cancer Res 1992;52:955-962.
24. Miller DA, Dev VG, Borek C, Miller OJ. The quinicrine fluorescent and Giemsa banding karyotype of the rat, Rattus norvegicus, and banded chromosome analysis of transformed and malignant cell clones. Cancer Res 1992;32:2375-2382.
25. Davisson MT, Lalley PA, Peters J, Doolittle DP, Hillyard AL, Searle AG. Report of the comparative committee for human, mouse, and other rodents. Cytogenet Cell Genet 1991;58:1152-1189.
26. Levan G, Szpirer C, Klinga K, Hanson C, Istain MQ. The gene map of the Norway rat (Rattus norvegicus) and comparative mapping with mouse and man. Genomics 1991;10:699-718.
27. Koufos A, Hansen MF, Copeland NG, Jenkins NA, Lampkin BC, Cavanee WK. Loss of heterozygosity in three embryonal tumors suggests a common pathogenic mechanism. Nature 1985;316:330-334.
28. Byrne JA, Simms LA, Little MH, Algar EM, Smith PJ. Three non-overlapping regions of chromosome arm 11p allele loss identified in infantile tumors of the adrenal and liver. Genes Chromosomes Cancer 1993;8:104-111.
29. Albrecht S, von Schweinitz D, Waha A, Kraus JA, von Deimling A, Pietsch T. Loss of maternal alleles on chromosome arm 11p in hepatoblastoma. Cancer Res 1994;54:5041-5044.
30. Grisham JW. Interspecies comparison of liver carcinogenesis: Implications for cancer risk assessment. Carcinogenesis 1997;18:59-81.
31. Coleman WB, McCullough KD, Esch GL, et al. Suppression of the tumorigenic phenotype of a rat liver epithelial tumor cell line by the p11.2-p12 region of human chromosome 11. Mol Carcinogenesis 1995;13:220-232.
32. Mahon MC, Driscoll MP, Glover WJ, et al. Suppression of tumorigenicity of rat liver epithelial tumor cell lines by a putative human 11p11.2-p12 liver tumor suppressor locus. Inter J Oncology 1999;14:337-346.
33. Coleman WB, Esch GL, Borchert KM, et al. Localization of a putative liver tumor suppressor locus to a 950-kb region of human 11pp11.2-p12 using rat liver tumor microcell hybrid cell lines. Mol Carcinogenesis 1997;19:267-272.
34. Ricketts SL, Garcia NF, Betz BL, Coleman WB. Identification of candidate liver tumor suppressor genes from human 11p11.2-p12. Genes Chromosomes Cancer 2002;33:47-59.
35. Tsao M-S, Grisham JW. Phenotypic modulation during tumorigenesis by clones of transformed rat liver epithelial cells. Cancer Res 1987;47:1282-1286.
36. Tsao M-S, Smith JD, Nelson KG, Grisham JW. A diploid epithelial cell line from normal adult rat liver with phenotypic properties of oval cells. Exp Cell Res 1984;154:38-52.
37. Lee LW, Raymond VW, Tsao MS, Lee DC, Earp HS, Grisham JW. Clonal cosegregation of tumorigenicity with overexpression of c-myc and transforming growth factor genes in chemically transformed rat liver epithelial cells. Cancer Res 1991;51:5238-5244.
38. Miller SA, Dykes DD, Polesky HF. A simple salting out procedure for extracting DNA from human nucleated cells. Nucl Acids Res 1988;16:1215.
39. The National Center for Biotechnology Information; http://www.ncbi.nlm.nih.gov
40. Glisin V, Crkvenjakov R, Byus C. Ribonucleic acid isolated by cesium chloride centrifugation. Biochemistry 1974;13:2633-2638.
41. Chirgwin J, Przybyla A, MacDonald R, Rutter W. Isolation of biologically active ribonucleic acid from sources enriched in ribonuclease. Biochemistry 1979;18:5294-5299.
42. Zimonjic DR, Keck CL, Thorgeirsson SS, Popescu NC. Novel recurrent genetic imbalances in human hepatocellular carcinoma cell lines identified by comparative genomic hybridization. Hepatology 1999;29:1208-1214.
43. Deloukas P, Schuler GD, Gyapay G, et al. A physical map of 30,000 human genes. Science 1998;282:744-746.
44. UCSC Genome Browser; http://genome.cse.ucsc.edu
45. Huang S, Shao G, Liu L. The PR domain of the Rb-binding zinc finger protein RIZ1 is a protein binding interface and is related to the SET domain functioning in chromatin-mediated gene expression. J Biol Chem 1998;273:15933-15939.
46. Jiang GL, Huang S. The yin-yang of PR-domain family genes in tumorigenesis. Histol Histopathol 2000;15:109-117.
47. Fang W, Piao Z, Simon D, Sheu J-C, Huang S. Mapping of a minimal deleted region in human hepatocellular carcinoma to 1p36.13-p36.23 and mutational analysis of the RIZ (PRDM2) gene located to the region. Genes Chromosomes Cancer 2000;28:269-275.
48. Polyak K, Xia Y, Zweier JL, Kinzler KW, Vogelstein B. A model for p53-induced apoptosis. Nature 1997;389:300-305.
49. Hollstein M, Sidransky D, Vogelstein B, Harris CC. p53 mutations in human cancers. Science 1991;253:49-53.
50. Greenblatt MS, Bennett WP, Hollstein M, Harris CC. Mutations in the p53 tumor suppressor gene: Clues to cancer etiology and molecular pathogenesis. Cancer Res 1994;54:4855-4878.
51. Hollstein M, Shomer B, Greenblatt M, et al. Somatic point mutations in the p53 gene of human tumors and cell lines: Updated compilation. Nucleic Acids Res 1996;24:141-146.
52. Hosono S, Lee C-S, Chou M-J, Yang C-S, Shih C. Molecular analysis of the p53 alleles in primary hepatocellular carcinomas and cell lines Oncogene 1991;6:237-243.
53. Goldblum JR, Bartos RE, Carr KA, Frank TS. Hepatitis B and alterations of the p53 tumor suppressor gene in hepatocellular carcinoma. Am J Surg Pathol 1993;17:1244-1251.
54. Ng IOL, Chung LP, Tsang SWY, et al. p53 gene mutation spectrum in hepatocellular carcinomas in Hong Kong Chinese. Oncogene 1994;9:985-990.
55. Qiu S-J, Ye S-L, Wu Z-Q, Tang Z-Y, Liu Y-K. The expression of the mdm2 gene may be related to the aberration of the p53 gene in human hepatocellular carcinoma. J Cancer Res Clin Oncol 1998;124:253-258.
56. Feitelson MA, Zhu M, Duan L-X, London WT. Hepatitis B x antigen and p53 are associated in vitro and in liver tissues from patients with primary hepatocellular carcinoma. Oncogene 1993;8:1109-1117.
57. Wang XW, Forrester K, Yeh H, Feitelson MA, Gu JR, Harris CC. Hepatitis B virus X protein inhibits p53 sequence-specific DNA binding, transcriptional activity, and association with transcription factor ERCC3. Proc Natl Acad Sci USA 1994;91:2230-2234.
58. Truant R, Antunovic J, Greenblatt J, Prives C, Cromlish JA. Direct interaction of the hepatitis B virus HBx protein with p53 leads to inhibition by HBx of p53 response element-directed transactivation. J Virol 1995;69:1851-1859.